Aspirin in primary prevention of cardiovascular disease in the elderly

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):326-327. doi: 10.1093/ehjcvp/pvz046.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Female
  • Hemorrhage / chemically induced
  • Humans
  • Male
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Primary Prevention*
  • Protective Factors
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Platelet Aggregation Inhibitors
  • Aspirin